Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Operating Expenses (2021 - 2025)

Historic Operating Expenses for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to $12.7 million.

  • SAB Biotherapeutics' Operating Expenses rose 1211.03% to $12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.3 million, marking a year-over-year decrease of 1873.12%. This contributed to the annual value of $44.2 million for FY2024, which is 972.02% up from last year.
  • Latest data reveals that SAB Biotherapeutics reported Operating Expenses of $12.7 million as of Q3 2025, which was up 1211.03% from $9.7 million recorded in Q2 2025.
  • SAB Biotherapeutics' Operating Expenses' 5-year high stood at $21.1 million during Q2 2021, with a 5-year trough of $6.6 million in Q2 2023.
  • For the 5-year period, SAB Biotherapeutics' Operating Expenses averaged around $12.9 million, with its median value being $11.4 million (2022).
  • The largest annual percentage gain for SAB Biotherapeutics' Operating Expenses in the last 5 years was 9138.82% (2023), contrasted with its biggest fall of 5687.23% (2023).
  • Over the past 5 years, SAB Biotherapeutics' Operating Expenses (Quarter) stood at $18.4 million in 2021, then plummeted by 45.55% to $10.0 million in 2022, then soared by 91.39% to $19.2 million in 2023, then tumbled by 47.21% to $10.1 million in 2024, then increased by 25.24% to $12.7 million in 2025.
  • Its last three reported values are $12.7 million in Q3 2025, $9.7 million for Q2 2025, and $10.8 million during Q1 2025.